impact factor, citescore
logo
 

Full Papers

 

Red blood cell distribution width as a surrogate biomarker of damage and disease activity in patients with systemic lupus erythematosus


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

 

  1. Division of Dermatology, Hospital Universitario de Canarias, Tenerife, Spain.
  2. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
  3. Division of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canarias, Spain.
  4. Division of Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canarias, Spain.
  5. Division of Central Laboratory, Hospital Universitario de Canarias, Tenerife, Spain.
  6. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain.
  7. Division of Dermatology, Hospital Universitario de Canarias, Tenerife, Spain.
  8. Division of Dermatology, Hospital Universitario de Canarias, Tenerife, Spain.
  9. Department of Internal Medicine. Universidad de La Laguna (ULL), Tenerife, Spain.
  10. Fundación Jiménez Díaz School of Nursing of Madrid, Autonomous University of Madrid, Spain.
  11. Division of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, and Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain. miguelaggay@hotmail.com
  12. Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, and Department of Internal Medicine. Universidad de La Laguna (ULL), Tenerife, Spain. iferrazamaro@hotmail.com

CER17267
2024 Vol.42, N°9
PI 1773, PF 1780
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 38757296 [PubMed]

Received: 03/11/2023
Accepted : 11/03/2024
In Press: 17/05/2024
Published: 23/09/2024

Abstract

OBJECTIVES:
Red blood cell distribution width (RDW) is a measure of variability in mean corpuscular volume. Alterations in RDW can be observed in a variety of human disorders, including inflammatory, cardiovascular, and hepatic or renal diseases. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect virtually any organ in the body. In this work, our objective was to analyse how a complete characterisation of disease characteristics in a large series of patients with SLE is related to RDW values.
METHODS:
284 patients with SLE and 181 age- and sex-matched healthy controls were recruited. Complete blood count including RDW was assessed. Multivariable analysis was performed to analyse the relationship between RDW and SLE disease characteristics, including composite scores of disease activity and damage.
RESULTS:
After multivariable adjustment, RDW was higher in patients with SLE compared to controls (beta coefficient 0.8 [95% confidence interval: 0.3–1] %, p=0.003). Several disease characteristics, such as the presence of extractable nuclear antibodies and antiphospholipid syndrome, and the use of prednisone and azathioprine, were significantly associated with higher levels of RDW after adjustment for confounders. Of note, cumulative disease damage and disease activity scores were associated with higher RDW values after controlling for covariates.
CONCLUSIONS:
RDW may serve as a surrogate biomarker of accrual disease damage and activity in patients with SLE.

DOI: https://doi.org/10.55563/clinexprheumatol/f0jnnm

Rheumatology Article